19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
22:26 , May 18, 2017 |  BC Innovations  |  Targets & Mechanisms

Degrading NASH

Inflammation is one of the primary drivers of non-alcoholic steatohepatitis (NASH), but decreasing inflammation without creating susceptibility to infection remains a challenge for the field. In Nature Medicine this month, a Chinese team described how...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Diacylglycerol O-acyltransferase-2 (DGAT2)

Endocrine/metabolic disease INDICATION: Dyslipidemia In vitro and mouse studies identified a DGAT2 inhibitor that could help treat dyslipidemia and other metabolic disorders. Screening of a small molecule library in enzymatic assays and optimization of hits yielded a...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Diacylglycerol O-acyltransferase-2 (DGAT2)

Endocrine/metabolic disease INDICATION: Hypercholesterolemia In vitro and mouse studies identified a DGAT2 inhibitor that could help treat hypercholesterolemia. Chemical synthesis and testing in DGAT2 activity assays of imidazopyridine analogs identified a compound that inhibited DGAT2 with an...
07:00 , Oct 28, 2010 |  BC Innovations  |  Cover Story

DGAT out of the bag

U.S. and French researchers have shown that DGAT1, an enzyme involved in lipid droplet biogenesis, is a host factor for HCV infection.1 The results have prompted Via Pharmaceuticals Inc.to consider repurposing its DGAT1 inhibitors, which...